Prescient Therapeutics advances innovative cancer therapies following successful FY 2021 – Small Caps

August 12, 2021

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s innovative pipeline of personalised cancer therapies.The company is developing customised approaches to treating cancer including targeted and cellular therapies.

Mr Yatomi-Clarke describes Prescient as a compelling investment case which is well-funded to deliver value-adding milestones across its various cancer treatments.

Watch to the full interview below.

Related Post

×